About
COVID-19 Vaccine
COVID 19-vaccines are effective at protecting people from getting seriously ill, being hospitalized, and dying. Vaccination remains the safest strategy for avoiding hospitalizations, long-term health outcomes, and death.
CDC recommends that all people aged 6 months and older stay up to date on COVID-19 vaccines. The FDA authorized the COVID-19 vaccines for the 2024-25 fall and winter virus season in August 2024.
COVID-19 Vaccination in the United States
Weekly cumulative percent of adults and children vaccinated with the updated 2024-25 COVID-19 vaccine. Refer to data notes for more details.
COVID-19 Vaccination Intent in the United States
Weekly intent for vaccination and cumulative percent of adults and children vaccinated with the updated 2024-25 COVID-19 vaccine. Refer to data notes for more details.
Flu Vaccine
Seasonal flu vaccines are designed to protect against infection and illness caused by the influenza viruses that research indicates will be most common during the upcoming flu season. Even when the viruses are different than expected, vaccination still protects against severe illness, hospitalization, and death.
CDC recommends that all people aged 6 months and older receive a seasonal flu vaccine. See additional data »
Flu Vaccination in the United States
Weekly cumulative percent of adults and children vaccinated with 2024-25 seasonal flu vaccine. Refer to data notes for more details.
Flu Vaccination Intent in the United States
Weekly intent for vaccination and cumulative percent of adults and children vaccinated with 2024-25 seasonal flu vaccine. Refer to data notes for more details.
RSV Vaccine
The RSV vaccine can prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms but may be especially serious for infants and older adults.
CDC recommends a single dose of RSV vaccine for all adults aged 75+ and for adults ages 60–74 years who are at increased risk of severe RSV. To prevent severe RSV disease in infants, CDC recommends either maternal RSV vaccination or infant immunization with nirsevimab, a monoclonal antibody product.
RSV Vaccination in the United States
Weekly cumulative percent of adults 75+ vaccinated with RSV vaccine. Refer to data notes for more details.
RSV Vaccination Intent in the United States
Weekly intent for vaccination and cumulative percent of adults 75+ vaccinated with RSV vaccine. Refer to data notes for more details.
Data Notes
- Source: National Immunization Survey-Flu (NIS-Flu).
- Additional information available at: About the National Immunization Surveys.
- Vaccination coverage estimates are based on all interviews through the current week and represent approximately the cumulative percent vaccinated by mid-week. Each week, estimates for prior weeks are recalculated using the additional interviews conducted that week (combined with all previous interviews). Estimates for vaccination intent are based on interviews conducted that week and are adjusted to the cumulative vaccination coverage estimate for that week.
- Confidence Intervals (CI) describe the level of uncertainty around an estimate because a sample was taken via a survey. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% CI, if the sampling method is repeated many times, the value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
- COVID-19 vaccination coverage estimates presented in this report represent uptake or intent for uptake of the 2024─25 COVID-19 vaccine. For children ≥5 years, up-to-date with the updated 2024─25 COVID-19 vaccine is defined as receipt of at least one vaccination since August 22, 2024. For children <5 years, up-to-date with the updated 2024─25 COVID-19 vaccine is defined based on the current recommendations that also take into account number of doses and brand of vaccine. Up-to-date status was determined by survey questions on month and year of most recent COVID-19 vaccine, and for children <5 years, total number of COVID-19 vaccinations received and brand of most recent COVID-19 vaccine.
- Estimates from the NIS-Flu may differ from estimates based on other data sources, and are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self or parental reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
- Source: National Immunization Survey-Adult COVID Module (NIS-ACM).
- Additional information available at: About the National Immunization Surveys.
- Vaccination coverage estimates are based on all interviews through the current week and represent approximately the cumulative percent vaccinated by mid-week. Each week, estimates for prior weeks are recalculated using the additional interviews conducted that week, combined with all previous interviews.
- Estimates for vaccination intent are based on interviews conducted that week and are adjusted to the cumulative vaccination coverage estimate for that week.
- Confidence Intervals (CI) describe the level of uncertainty around an estimate because a sample was taken via a survey. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% CI, if the sampling method is repeated many times, the value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
- COVID-19 vaccination coverage estimates presented in this report represent uptake or intent for uptake of the updated 2024-25 COVID-19 vaccine.
- Estimates for RSV vaccination among adults ages 60-74 at increased risk of severe RSV disease are shown on RSVVaxView.
- Estimates from the NIS-ACM may differ from estimates based on other data sources, and are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self or parental reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.